A phase I trial to evaluate OTX-TKI.

Trial Profile

A phase I trial to evaluate OTX-TKI.

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs OTX-TKI (Primary)
  • Indications Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Nov 2017 According to an Ocular Therapeutix media release, Company expects to initiate this trial outside the United States for OTX-TKI in the first half of 2018.
    • 08 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2017, according to an Ocular Therapeutix media release.
    • 22 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top